← All trials
NCT05184335
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Jan 24, 2022
- Primary completion
- Dec 20, 2023
- Completion date
- Dec 20, 2023
- First posted
- Jan 11, 2022
- Last posted
- Apr 11, 2022
- Enrollment
- 402
- Arms / groups
- 3 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Reviva PharmaceuticalsLead sponsor
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.